In veterinary tablet manufacturing, Lifei Zhike Powder Veterinary Grade API enters the process stream only after release testing confirms a particle size distribution with D90 ≤ 150 µm by laser diffraction (ISO 13320:2020) and residual moisture ≤ 1.0% by USP <921>. The tablet formulation window sets the API fraction in the core at 8–35 wt% for direct compression when the target unit dose is between 5 mg and 150 mg; high-dose tablets of 200–500 mg require dry granulation and may reach 65–75 wt% API, because direct compression beyond this level can reduce compact tensile strength below 1.5 MPa and raise friability above 1.0% under USP <1216>. Manufacture is conducted under Regulation (EU) 2019/6 for veterinary medicinal products and Commission Delegated Regulation (EU) 1252/2014 for active substances used as starting materials, while finished product release includes USP <905> uniformity of dosage units and USP <711> dissolution. The production sequence uses a 1,000 L bin blender at 6–12 rpm for 15–20 min for pre-blending, roller compaction at 4–6 MPa when dry granulation is selected, compression on a rotary tablet press at 12–25 kN, and aqueous film coating to 2.0–4.0 wt% gain in a perforated pan. Terminal stock-keeping units include scored tablets, chewable tablets, and film-coated tablets packed in blister or HDPE containers for companion animals and livestock. A process boundary is humidity: at RH > 60%, punch sticking and weight variability above RSD 2.0% are documented failure modes; magnesium stearate is therefore limited to ≤ 0.5 wt% to avoid dissolution retardation.

What F0 and Sterile Filtration Limits Apply to Aqueous Veterinary Injection Manufacturing?

Aqueous injectable solutions based on this veterinary API require solubility and buffer stability screening across pH 2.0–7.0 at 0.1 M ionic strength before scale-up, because the final pH is constrained by the route of administration and by the molecule’s hydrolytic sensitivity. The API addition ratio is typically 0.1–20.0% w/v, with osmolality adjusted to 280–320 mOsm/kg using sodium chloride at 0.6–0.9% w/v or dextrose at 4.0–5.0% w/v under USP <785>. Compliance is governed by EU GMP Annex 1 for sterile manufacturing, USP <1> Injections, USP <85> Bacterial Endotoxins, USP <788> Particulate Matter, and ISO 14644-1:2015 class 5 in the filling zone. The production sequence includes dissolution in WFI at 20–40°C, pH adjustment with 0.1 mol/L HCl or NaOH, nitrogen blanketing if oxidative degradation is observed during forced degradation, filtration through a 0.45 µm prefilter and a 0.22 µm PES sterilising filter validated by ASTM F838-20, and aseptic filling into depyrogenated Type I glass vials. If the API exhibits a D-value that supports terminal sterilisation, an autoclave cycle at 121°C for 15 min with F0 ≥ 12 may replace sterile filtration; otherwise, the solution is sterile-filtered and filled under aseptic conditions. Filled vial formats include 10 mL, 50 mL, and 100 mL single-dose or multi-dose vials for bovine, equine, and companion-animal parenteral administration. A critical limitation is that phosphate buffers should be avoided if polyvalent cations are present, and filter compatibility must be confirmed at the target pH because PES membranes can release extractables under strongly alkaline conditions.

Feed Premix Dilution, Carryover, and Homogeneity Specifications in Swine and Poultry Lines

Feed premix operations using this veterinary-grade powder as the active substance are based on geometric dilution rather than high-shear mixing, because the active fraction is too low for direct addition to finished feed without segregation and recovery drift. The primary premix is produced at 1.0–10.0% w/w API in a carrier of lactose monohydrate or milled rice hulls, with final in-feed inclusion calculated at 0.5–5.0 kg/t of finished feed to deliver the prescribed daily dose; finished feed homogeneity must meet a coefficient of variation RSD ≤ 5.0% under Regulation (EU) 2019/4 on medicated feed, and assay recovery in 10 sampling points should fall within 90–110% of the theoretical concentration. Production equipment is typically a 500 kg double-ribbon blender operated at 20–25 rpm for 20–30 min, with the API pre-blended at 1:10 into carrier before introduction into the main mixer to prevent dead zones near the shaft seals. A documented carryover control programme is required, including swab limits and periodic verification after the batch transfer line, because cross-contamination into non-medicated feed is a regulatory threshold issue under medicated feed legislation. Terminal formats include 1 kg, 5 kg, and 20 kg foil-lined premix bags, oral powder sachets for direct administration, and water-soluble powder buckets for drinking-line delivery. Storage should remain below 25°C and 60% RH to avoid caking; if the API particle size is below 50 µm, electrostatic segregation during mixer discharge becomes a documented batch-to-batch variance source that can shift recovery outside the 90–110% window.

Low-dose capsule formulations of this veterinary API often require a pre-blend of the active with lactose monohydrate or microcrystalline cellulose at a ratio of 1:9 to 1:19 before main mixing, because the pure API’s cohesive nature can cause fill weight drift above RSD 2.0% on dosator-type capsule machines. The addition ratio for the filled powder is 5–30 wt% API depending on unit dose, with individual fill weights from 25 mg to 250 mg across capsule sizes 0 to 3. The production line includes de-lumping through an 0.8 mm screen, low-shear bin blending for 15 min, lubrication with 0.25–0.5 wt% magnesium stearate, and automatic capsule filling with in-process fill weight checks every 15 min. Release testing follows USP <905> Uniformity of Dosage Units, USP <711> Dissolution, and Ph. Eur. 2.9.40 uniformity of dosage units. The filling suite is maintained at 35–45% RH to prevent gelatin shell deformation and powder moisture uptake. Terminal products are hard gelatin or HPMC capsules in blister packs and bottles for companion animals.

When Wet Granulation Replaces Direct Blending for Dose Uniformity in Multi-Species Granules

When the target unit dose is below 10 mg per granule sachet or when the API exhibits high fines content and poor flow, wet granulation is used to densify the active into a granule matrix and prevent segregation during packaging. The formulation addition window for oral granules is 1.0–20.0% w/w API, with binder solution added at 8–12% relative to dry powder mass; polyvinylpyrrolidone K30 is typically used at 2–5 wt% of dry solids and dissolved in purified water or a water–ethanol mixture at 60–70°C before addition. Stability obligations are set under VICH GL1, and dried granule moisture is controlled by Ph. Eur. 2.2.32 loss on drying. The process sequence uses a 300 L high-shear mixer at impeller 150–200 rpm and chopper 1,000–1,500 rpm for 3–5 min, wet massing through a 1.5 mm screen, fluid-bed drying at inlet 60–70°C and product temperature 35–40°C to LOD ≤ 2.5%, and final sieving to 0.5–2.0 mm. The main process conflict is endpoint control: over-granulation densifies the granules and slows dissolution, while under-granulation leaves friable granules with dust generation and poor flow into packaging equipment. Terminal product forms are 0.5–2.0 mm granules packed in aluminium sachets, polypropylene jars, or top-dress packs for equine, cattle, swine, and poultry use.

Oral Drench and Drinking Water Solutions Are Governed by Co-Solvent Ratio and pH Boundaries

Oral liquid dosage forms using this veterinary API are formulated as true solutions or as cosolvent systems, with the API fraction set between 0.5% and 10.0% w/v according to the target dose per mL and palatability constraints for the target species. Propylene glycol is maintained at 5–20% v/v and glycerin at 5–15% v/v to reduce the dielectric constant of the vehicle and improve dissolution, while potassium sorbate at 0.1–0.2% w/v or sodium benzoate at 0.1% w/v is added as preservative when multi-dose containers are used. The production line uses a jacketed stainless steel vessel at 20–25°C, dissolution under low-shear agitation, pH adjustment to a target that avoids precipitation, makeup to final volume with deionized water, and filtration through a 10 µm clarifying filter before filling. The product must meet Regulation (EU) 2019/6 and is released under pH, assay, and preservative efficacy testing; stability is evaluated per VICH GL3, and photostability per VICH GL5 when the API has light sensitivity. Critical boundaries include avoidance of pH values above 6.0 if forced degradation shows alkaline hydrolysis, and exclusion of oxidising excipients if the molecule is electron-rich. Terminal products include 10 mL, 100 mL, and 1 L oral drench bottles, 5 L drinking water containers, and calibrated pump-dispenser packs for swine and poultry.